Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 931

1.

[Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].

Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.

Vnitr Lek. 2011 Feb;57(2):189-213. Review. Czech.

PMID:
21416861
2.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.

PMID:
16919893
3.

Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.

Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Thiele J, et al.

Neth J Med. 1999 Feb;54(2):46-62. Review.

PMID:
10079679
4.

The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.

Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. Review.

PMID:
16810609
5.

Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.

Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.

Semin Thromb Hemost. 2006 Apr;32(3):174-207. Review.

PMID:
16673274
6.

WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.

Michiels JJ, De Raeve H, Hebeda K, Lam KH, Berneman Z, Schroyens W, Schwarz J.

Leuk Res. 2007 Aug;31(8):1031-8. Epub 2007 Mar 23. Review.

PMID:
17367853
7.
8.

Analysis of risk factors: the rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia.

Schwarz J, Pytlík R, Doubek M, Brychtová Y, Dulícek P, Campr V, Kren L, Penka M.

Semin Thromb Hemost. 2006 Apr;32(3):231-45.

PMID:
16673277
10.

Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.

Michiels JJ, Berneman Z, Schroyens W, De Raeve H.

Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7. Review.

PMID:
25116092
11.

Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.

Tefferi A, Barbui T.

Am J Hematol. 2017 Jan;92(1):94-108. doi: 10.1002/ajh.24607.

PMID:
27991718
12.

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.

Eur J Haematol. 2007 Dec;79(6):508-15. Epub 2007 Oct 23.

PMID:
17961178
13.

The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods.

Lucia E, Martino B, Mammi C, Vigna E, Mazzone C, Gentile M, Qualtieri G, Bisconte MG, Naccarato M, Gentile C, Laganà C, Romeo F, Neri A, Nobile F, Morabito F.

Leuk Lymphoma. 2008 Oct;49(10):1907-15. doi: 10.1080/10428190802290652.

PMID:
18720212
14.

The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.

Rudzki Z, Sacha T, Stój A, Czekalska S, Wójcik M, Skotnicki AB, Grabowska B, Zduńczyk A, Okoń K, Stachura J.

Int J Hematol. 2007 Aug;86(2):130-6.

PMID:
17875526
16.

[Myeloproliferative diseases caused by JAK2 mutation].

Nagata K, Shimoda K.

Rinsho Byori. 2009 Apr;57(4):357-64. Review. Japanese.

PMID:
19489438
17.

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.

Tefferi A, Barbui T.

Am J Hematol. 2015 Feb;90(2):162-73. doi: 10.1002/ajh.23895. Review. Erratum in: Am J Hematol. 2015 Sep;90(9):849.

19.

Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.

Tefferi A.

Am J Hematol. 2012 Mar;87(3):285-93. doi: 10.1002/ajh.23135. Review.

20.

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.

Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.

Exp Hematol. 2009 Oct;37(10):1186-1193.e7. doi: 10.1016/j.exphem.2009.07.005. Epub 2009 Jul 17.

PMID:
19616600

Supplemental Content

Support Center